Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals

Biochemistry (Mosc). 2016 Nov;81(11):1396-1400. doi: 10.1134/S000629791611016X.


Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient's immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring anti-human IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology*
  • Cell Line, Tumor
  • Drug Resistance / drug effects*
  • Drug Resistance / immunology
  • Female
  • Humans
  • Interferon-beta / administration & dosage*
  • Interferon-beta / adverse effects
  • Interferon-beta / immunology
  • Male
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*


  • Antibodies, Neutralizing
  • Interferon-beta